Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

Leukemia

Volumn 29, Issue 11, 2015, Pages 2238-2247

  Zhao, Q ^a   Ahmed, M ^a   Tassev, D V ^a   Hasan, A ^a   Kuo, T Y ^a   Guo, H F ^a   O'Reilly, R J ^a   Cheung, N K V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPITOPE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; SCFV HULGG1 FC FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T CELL RECEPTOR LIKE ANTIBODY; TUMOR PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR 1 PROTEIN; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT; PEPTIDE LIBRARY; WT1 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MALE; MOUSE; MUTAGENESIS; NATURAL KILLER CELL; NEPHROBLASTOMA; NONHUMAN; PEPTIDE LIBRARY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT; YEAST; ANIMAL; ANTIBODY AFFINITY; EPITOPE MAPPING; IMMUNOLOGY;

ANIMALS; ANTIBODY AFFINITY; CELL LINE, TUMOR; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; MALE; MICE; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES; WT1 PROTEINS;

EID: 84946494672     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.125     Document Type: Article

References (50)

1. Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 2012; 120: 1633-1646.
2. Santomasso BD, Roberts WK, Thomas A, Williams T, Blachere NE, Dudley ME et al. A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci USA 2007; 104: 19073-19078.
3. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541-6548.
4. Yee C. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med 2005; 3: 17.
5. Dahan R, Reiter Y. T-cell-receptor-like antibodies-generation, function and applications. Expert Rev Mol Med 2012; 14: e6.
6. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit 2003; 16: 324-332.
7. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci USA 2000; 97: 7969-7974.
8. Lev A, Noy R, Oved K, Novak H, Segal D, Walden P et al. Tumor-specific Abmediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci USA 2004; 101: 9051-9056.
9. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA 2009; 106: 5784-5788.
10. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003; 4: 55-62.
11. Denkberg G, Reiter Y. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation. Autoimmun Rev 2006; 5: 252-257.
12. Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javiad A et al. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol 2011; 85: 1935-1942.
13. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011; 117: 4262-4272.
14. Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA et al. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol 2010; 184: 2156-2165.
15. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 2001; 8: 1601-1608.
16. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013; 5: 176ra133.
17. Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 2012; 19: 84-100.
18. Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol 2014; 193: 5733-5743.
19. Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD, Wancewicz EV et al. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol Cancer Ther 2004; 3: 1467-1484.
20. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: The WT1 story. Leukemia 2007; 21: 868-876.
21. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 2010; 40: 377-387.
22. O'Reilly RJ, Dao T, Koehne G, Scheinberg D, Doubrovina E. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin Immunol 2010; 22: 162-172.
23. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK et al. T-cell responses directed against multiple HLA-A∗0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11: 8799-8807.
24. Kohrt HE, Muller A, Baker J, Goldstein MJ, Newell E, Dutt S et al. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood 2011; 118: 5319-5329.
25. Borbulevych OY, Do P, Baker BM. Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A∗0201: implications for WT1-based cancer therapeutics. Mol Immunol 2010; 47: 2519-2524.
26. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-166.
27. de Wildt RM, Mundy CR, Gorick BD, Tomlinson IM. Antibody arrays for highthroughput screening of antibody-antigen interactions. Nat Biotechnol 2000; 18: 989-994.
28. Zhao Q, Zhu Z, Dimitrov DS. Yeast display of engineered antibody domains. Methods Mol Biol 2012; 899: 73-84.
29. Zhao Q, Chan YW, Lee SS, Cheung WT. One-step expression and purification of single-chain variable antibody fragment using an improved hexahistidine tag phagemid vector. Protein Expr Purif 2009; 68: 190-195.
30. Chen W, Feng Y, Zhao Q, Zhu Z, Dimitrov DS. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics. Mol Cancer Ther 2012; 11: 1400-1410.
31. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1: 477-486.
32. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-684.
33. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012; 503: 255-268.
34. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon? Methods Mol Biol 2009; 525: 1-27, xiii.
35. Zhao Q, Feng Y, Zhu Z, Dimitrov DS. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity. Mol Cancer Ther 2011; 10: 1677-1685.
36. Li Y, Li H, Yang F, Smith-Gill SJ, Mariuzza RA. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat Struct Biol 2003; 10: 482-488.
37. Mareeva T, Martinez-Hackert E, Sykulev Y. How a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptide. J Biol Chem 2008; 283: 29053-29059.
38. Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptorlike human recombinant antibodies. Eur J Immunol 2008; 38: 1706-1720.
39. Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y et al. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. Expert Rev Anticancer Ther 2005; 5: 523-536.
40. Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol 2011; 86: 31-37.
41. Engberg J, Yenidunya AF, Clausen R, Jensen LB, Sorensen P, Kops P et al. Human recombinant Fab antibodies with T-cell receptor-like specificities generated from phage display libraries. Methods Mol Biol 2003; 207: 161-177.
42. Gilham DE, Debets R, Pule M, Hawkins RE, Abken H. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 2012; 18: 377-384.
43. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011; 11: 855-873.
44. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia. Blood 2013; 122: 3138-3148.
45. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13: 397-411.
46. Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies SD et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012; 16: 569-581.
47. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA 2008; 105: 17481-17486.
48. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D.. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010; 16: 3901-3909.
49. Shook DR, Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 2011; 78: 409-415.
50. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.